// App-Quantinova.ai

314 : Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

Researchers

Presenter

  • Cristiane Decat Bergerot

Principal Investigators

  • Sun Young Rha

  • Sumanta K. Pal

  • Piotr Koralewski

  • Daniil Stroyakovskiy

  • Boris Alekseev

  • Francis Parnis

  • Daniel Castellano

  • Jae-Lyun Lee

  • Kaisa Sunela

  • Tudor Ciuleanu

  • Daniel Yick Chin Heng

  • Hilary Glen

  • Jinyi Wang

  • Lee Bennett

  • Janice Pan

  • Karen O'Hara

  • Javier Puente

Medical Centers

  • Centro de Cncer de Brasilia (CETTRO), Brasilia, Brazil

  • Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea

  • Szpital Specjalistyczny Ludwika Rydygier, Kraków, Poland

  • Moscow City Oncology Hospital No62 of Moscow Department of Health, Moscow, Russian Federation

  • Research Oncology Institute, Tomsk, Russian Federation

  • University of Adelaide, Adelaide, Australia

  • 12 de Octubre Universitary Hospital, Madrid, Spain

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Department of Oncology, Tampere University Hospital, Tampere, Finland

  • Prof. Dr. I. Chiricuta Institute of Oncology, Napoca, Romania

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Medical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • RTI Health Solutions, Research Triangle Park, NC

  • Eisai Inc, Woodcliff Lake, NJ

  • Eisai Ltd., Hatfield, United Kingdom

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

Locations

  • Brazil

  • Republic of South Korea

  • United States

  • Poland

  • Russia

  • Australia

  • Spain

  • Finland

  • Romania

  • Canada

  • United Kingdom

Companies

  • RTI Health Solutions

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • EORTC

  • NCT03173560

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved